Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2023

Protein Sciences [Member] | QT Holdings Corporation [Member]

The related nine months ended March 31, 2023 restructuring charges were recorded in the income statement as follows (in thousands):


	Employee		Asset
	severance		impairment and other		Total
Selling, general and administrative	$	1,328	$	842	$	2,170


	Employee		Asset
	severance		impairment and other		Total
Expense incurred in the first quarter of 2023	$	1,328	$	842	$	2,170
Cash payments		(420)		(431)		(851)
Adjustments		—		(72)		(72)
Accrued restructuring actions balances as of September 30, 2022		908		339		1,247
Cash payments		(753)		(262)		(1,015)
Adjustments		(38)		(73)		(111)
Accrued restructuring actions balances as of December 31, 2022		117		4		121
Cash payments		(60)		(70)		(130)
Adjustments		(57)		75		18
Accrued restructuring actions balances as of March 31, 2023	$	—	$	9	$	9

Protein Sciences [Member] | Employee Severance [Member]

Notes Tables

Schedule of restructuring charges

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):


	Employee
	severance
Expense incurred in the second quarter of 2023	$	780
Cash payments		(176)
Adjustments		—
Accrued restructuring actions balances as of December 31, 2022		604
Cash payments		(586)
Adjustments		(18)
Accrued restructuring actions balances as of March 31, 2023	$	—

Diagnostics and Genomics [Member]

Notes Tables

Schedule of restructuring charges

Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within Operating Income on the Income statement as follows (in thousands):


	Employee		Asset
	severance		impairment and other		Total
Selling, general and administrative	$	649	$	750	$	1,399

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):


	Employee		Asset
	severance		impairment and other		Total
Expense incurred in the first quarter of 2022	$	639	$	546	$	1,185
Incremental expense incurred during fiscal 2022		—		242		242
Cash payments		(589)		(554)		(1,143)
Adjustments⁽¹⁾		(50)		(234)		(284)
Accrued restructuring actions balances as of June 30, 2022	$	—	$	—	$	—

⁽¹⁾Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.